Paclitaxel with Cisplatin as Salvage Treatment for Patients with Previously Treated Advanced Transitional Cell Carcinoma of the Urothelial Tract

• Published in: Neoplasia (New York, N.Y.) N.Y.), 2007-01, Vol.9 (1), p.18-22
• Main Authors: Uhm, Ji Eun, Lim, Ho Yeong, Kim, Won Seog, Choi, Han Yong, Lee, Hyun Moo, Park, Byeong-Bae, Park, Keunchil, Kang, Won Ki
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Carcinoma, Transitional Cell - drug therapy; Carcinoma, Transitional Cell - mortality; cisplatin; Cisplatin - administration & dosage; Cisplatin - adverse effects; Epirubicin - administration & dosage; Female; Humans; Male; Methotrexate - administration & dosage; Middle Aged; Paclitaxel; Paclitaxel - administration & dosage; Paclitaxel - adverse effects; Salvage Therapy; transitional cell carcinoma; Urinary Bladder Neoplasms - drug therapy; Urinary Bladder Neoplasms - mortality; urothelium; Vinblastine - administration & dosage
• ISSN: 1476-5586; 1522-8002; 1476-5586; 1522-8002
• DOI: 10.1593/neo.06661

BACKGROUND: This study was performed to evaluate the safety and efficacy of paclitaxel with cisplatin as salvage therapy in patients previously treated with gemcitabine and cisplatin (G/C) for advanced transitional cell carcinoma (TCC) of the urothelial tract. METHODS: Twenty-eight patients with metastatic or locally advanced TCC who had received prior G/C chemotherapy were enrolled. All patients received paclitaxel (175 mg/m2) and cisplatin (60 mg/m2) every 3 weeks for eight cycles or until disease progression. RESULTS: The median age was 61 years (range, 43–83 years), and the median Eastern Cooperative Oncology Group performance status was 1 (range, 0–2). The overall response rate was 36% [95% confidence interval (95% CI) = 18–54], with three complete responses and seven partial responses. The median time to progression was 6.2 months (95% CI = 3.9–8.5), and the median overall survival was 10.3 months (95% CI = 6.1–14.1). The most common Grade 3/4 nonhematologic and hematologic toxicities were emesis (10 of 28 patients; 36%) and neutropenia (5 of 110 cycles; 5%). CONCLUSIONS: Salvage chemotherapy with paclitaxel and cisplatin displayed promising results with tolerable toxicity profiles in patients with metastatic or locally advanced TCC who had been pretreated with G/C.